OncoMatch/Clinical Trials/NCT07315113
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Is NCT07315113 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NXP900 and Osimertinib for egfr mutation positive non-small cell lung cancer.
Treatment: NXP900 · Osimertinib — This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR mutation
EGFR-mutated NSCLC
Excluded: EGFR mutation causing resistance to osimertinib
Known EGFR mutations that cause resistance to osimertinib
Excluded: HER2 (ERBB2) overexpression
Known human epidermal growth factor receptor 2 (HER2) overexpression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: EGFR tyrosine kinase inhibitor (osimertinib) — first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting
Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Massachusetts General Hospital · Boston, Massachusetts
- NEXT Houston · Houston, Texas
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify